The epidermal growth factor receptor (EGFR) in head and neck cancer: Its role and treatment implications

147Citations
Citations of this article
130Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. Its stimulation by endogenous ligands, EGF or transforming growth factor-alpha (TGF-α) results in activation of intracellular tyrosine kinase, therefore, cell cycle progression. High levels of EGFR expression are correlated with poor prognosis and resistance to radiation therapy in a variety of cancers, mostly in squamous-cell carcinoma of the head and neck (SCCHN). Blocking the EGFR by a monoclonal antibody results in inhibition of the stimulation of the receptor, therefore, in inhibition of cell proliferation, enhanced apoptosis, and reduced angiogenesis, invasiveness and metastases. The EGFR is a prime target for new anticancer therapy in SCCHN, and other agents in development include small molecular tyrosine kinase inhibitors and antisense therapies. © 2006 Zimmermann et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Zimmermann, M., Zouhair, A., Azria, D., & Ozsahin, M. (2006, May 2). The epidermal growth factor receptor (EGFR) in head and neck cancer: Its role and treatment implications. Radiation Oncology. https://doi.org/10.1186/1748-717X-1-11

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free